section name header

Pronunciation

te-NOE-fo-veer al-a-FEN-a-mide

Classifications

Therapeutic Classification: antiretrovirals

Pharmacologic Classification: nucleoside reverse transcriptase inhibitors

Indications

REMS


Action

  • Converted by hydrolysis to tenofovir and subsequently phosphorylated to the active metabolite, tenofovir diphosphate, which inhibits replication of HBV through incorporation into viral DNA by the HBV reverse transcriptase resulting in disruption of DNA synthesis.
Therapeutic effects:
  • Decreased progression/sequelae of chronic HBV infection.

Pharmacokinetics

Absorption: Tenofovir alafenamide is a prodrug, which is hydrolyzed into tenofovir; absorption enhanced by high-fat meals.

Distribution: Unknown.

Metabolism/Excretion: Tenofovir is phosphorylated to tenofovir diphosphate (active metabolite); 32% excreted in feces, <1% in urine.

Half-Life: 0.51 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown0.5 hr24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

GI: amylase, liver enzymes, abdominal pain, LACTIC ACIDOSIS/HEPATOMEGALY WITH STEATOSIS, nausea

GU: ACUTE RENAL FAILURE/FANCONI SYNDROME, glycosuria

Metab: hyperlipidemia

MS: creatine kinase, back pain

Neuro: fatigue, headache

Resp: cough

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Renal Impairment

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Vemlidy